History of passive antibody administration for prevention and treatment of infectious diseases

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 129-134

  Graham, Barney S ^a   Ambrosino, Donna M ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ClearPath Vaccines Company (CVC)   (United States)

Author keywords

history; immunoglobulin; Keywords antibody; passive immunization; serum therapy

Indexed keywords

IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY STRUCTURE; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; COMMUNICABLE DISEASES; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; COMMUNICABLE DISEASES; HUMANS; IMMUNIZATION, PASSIVE;

EID: 84928571820     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000154     Document Type: Review

References (29)

1. Winau F, Winau R. Emil von Behring and serum therapy. Microbes Infection 2002; 4:185-188.
2. Lindenmann J. Origin of the terms 'antibody' and 'antigen'. Scand J Immunol 1984; 19:281-285.
3. Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de serum antidiptherique. [Regarding the abnormal increase of antitoxin in horses producing antidiphtheria serum.] Bull Soc Centr Med Vet 1925; 101:227-234.
4. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
5. Janeway CA. Use of concentrated human gamma globulin in the prevention and attenuation of measles. Bull NY Acad Med 1945; 21:202-212.
6. Hammon WM, Coriell LL, Wehrle PF, Stokes J Jr. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc 1953; 151:1272-1285.
7. Alexander HE, Leidy G, et al. Hemophilus influenzae meningitis treated with streptomycin. J Am Med Assoc 1946; 132:434-440.
8. Casadevall A, Scharff MD. Serum therapy revisited: Animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38:1695-1702.
9. Heidelberger M, AveryOT. The soluble specific substance of pneumococcus. J Exp Med 1923; 38:73-79.
10. Heidelberger M, Avery OT. The soluble specific substance of pneumococcus: second paper. J Exp Med 1924; 40:301-317.
11. Heidelberger M, Kendall FE. A quantitative study of the precipitin reaction between type Iii pneumococcus polysaccharide and purified homologous antibody. J Exp Med 1929; 50:809-823.
12. Kendrick DB. Blood Program in World War II. Washington DC: US Government Printing Office; 1964; 922 p.
13. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 1997; 99:93-99.
14. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56:919-922.
15. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 (Suppl 1):S18-23.
16. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2:1216-1217.
17. Enria DA, Briggiler AM, Sanchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res 2008; 78:132-139.
18. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994; 23:23-31.
19. Enria DA, Briggiler AM, Fernandez NJ, et al. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984; 2:255-256.
20. Kö hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497.
21. Steinitz M, Klein G, Koskimies S,Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977; 269:420-422.
22. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348:552-554.
23. Green LL, Hardy MC, Maynard-Currie CE, et al. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 1994; 7:13-21.
24. Lonberg N, Taylor LD, Harding FA, et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 1994; 368:856-859.
25. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298:2199-2202.
26. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-671.
27. Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455:532-536.
28. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
29. Tiller T, Meffre E, Yurasov S, et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-124.